Neumora (NMRA-511): Encouraging Early Alzheimer’s Agitation Data but Mixed V1a History and Valuation Keep Risk-Reward Balanced at Hold

William Blair analyst Myles Minter has maintained their neutral stance on NMRA stock, giving a Hold rating on December 30.

Myles Minter has given his Hold rating due to a combination of factors related to both promise and remaining uncertainty in Neumora’s NMRA-511 program. The Phase 1b Alzheimer’s agitation data showed encouraging signs of clinical activity, particularly in patients with higher baseline anxiety, but the study was small, not designed to prove efficacy, and the primary agitation measure did not reach statistical significance. He sees the planned higher-dose extensions and the move to a once-daily formulation as sensible next steps that could both optimize efficacy and extend the drug’s intellectual property life if successful. At the same time, he notes that the history of V1a receptor antagonists in other indications has been mixed, which tempers confidence until more robust, dose-optimized data are available.

Minter also views NMRA-511’s emerging safety and tolerability profile as a relative advantage versus currently approved options like Rexulti, particularly given concerns about mortality warnings for antipsychotics in this population. The ability to explore higher doses without clear safety barriers could, in his view, translate into stronger efficacy signals in later-stage studies, but this remains to be demonstrated in larger, pivotal trials. He recognizes that the company’s decision to progress toward a Phase II/III design similar to successful precedents is strategically sound, yet believes the current valuation already reflects much of this optionality. As a result, he concludes that the risk-reward is balanced at present, justifying a Hold rating while awaiting clearer data from upcoming dose-finding and registrational efforts.

In another report released on December 30, TipRanks – OpenAI also upgraded the stock to a Hold with a $1.50 price target.